Laurus Labs Limited Stock price

Equities

LAURUSLABS

INE947Q01028

Pharmaceuticals

Delayed NSE India S.E. 08:02:00 2024-03-28 am EDT 5-day change 1st Jan Change
392.4 INR +0.04% Intraday chart for Laurus Labs Limited +2.20% -8.80%
Sales 2024 * 50.56B 607M Sales 2025 * 58.93B 707M Capitalization 211B 2.54B
Net income 2024 * 1.96B 23.46M Net income 2025 * 4.5B 53.98M EV / Sales 2024 * 4.58 x
Net Debt 2024 * 20.12B 241M Net Debt 2025 * 20.75B 249M EV / Sales 2025 * 3.94 x
P/E ratio 2024 *
110 x
P/E ratio 2025 *
46.2 x
Employees 5,753
Yield 2024 *
0.34%
Yield 2025 *
0.42%
Free-Float 65.41%
More Fundamentals * Assessed data
Dynamic Chart
Laurus Labs, Slovenia's Krka to Form JV; Laurus Shares Fall 6% MT
Laurus Labs Limited Reaches to Agreement with Krka to Establish Joint Venture Company in Hyderabad, India Namely Krka Pharma Pvt. Ltd CI
Jefferies Adjusts Laurus Labs’ Price Target to INR250 From INR290, Keeps at Underperform MT
Laurus Labs Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023 CI
Transcript : Laurus Labs Limited, Q3 2024 Earnings Call, Jan 24, 2024
INDIA STOCKS-IT drives losses in Indian shares ahead of Fed policy outcome RE
Indian shares set to open higher; focus turns to Fed policy RE
Laurus Labs Completes Acquisition of Additional Stake in Laurus Bio MT
Laurus Labs Limited completed the acquisition of additional 14.54% stake in Laurus Bio Private Limited from one of the Promoters, non-executive director, his family members and few Employee/ex-Employee shareholders. CI
Jefferies Adjusts Laurus Labs’ Price Target to INR260 From INR250, Keeps at Underperform MT
Laurus Labs Limited Announces Resignation of Chandrakanth Chereddi as Non-Executive Director CI
Transcript : Laurus Labs Limited, Q2 2024 Earnings Call, Oct 20, 2023
Laurus Labs Limited Approves Interim Dividend, Payable on or After November 09, 2023 CI
Laurus Labs Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023 CI
Laurus Labs Limited agreed to acquire an additional 14.54% stake in Laurus Bio Private Limited from one of the Promoters, non-executive director, his family members and few Employee/ex-Employee shareholders for approximately INR 720 million. CI
More news
1 day+0.04%
1 week+2.20%
Current month-3.37%
1 month-3.14%
3 months-8.06%
6 months+0.37%
Current year-8.80%
More quotes
1 week
389.55
Extreme 389.55
404.90
1 month
373.10
Extreme 373.1
425.85
Current year
360.85
Extreme 360.85
444.70
1 year
278.85
Extreme 278.85
444.70
3 years
278.85
Extreme 278.85
723.75
5 years
59.00
Extreme 59
723.75
10 years
59.00
Extreme 59
723.75
More quotes
Managers TitleAgeSince
Founder 63 05-09-18
Director of Finance/CFO - 06-11-29
Chief Operating Officer - 08-04-01
Members of the board TitleAgeSince
Founder 63 05-09-18
Chairman 83 17-05-23
Director/Board Member 68 -
More insiders
Date Price Change Volume
24-03-28 392.4 +0.04% 1,534,903
24-03-27 392.2 -1.37% 1,786,066
24-03-26 397.6 -0.04% 2,861,670
24-03-22 397.8 +3.62% 2,124,198
24-03-21 383.9 +1.28% 3,729,334

Delayed Quote NSE India S.E., March 28, 2024 at 08:02 am EDT

More quotes
Laurus Labs Limited is an India-based pharmaceutical and biotechnology company. The Company offers integrated portfolio of Active Pharma Ingredients (API) including intermediates, Generic Finished dosage forms (FDF) and Contract Research services to cater to the needs of the global pharmaceutical industry. The Company operates through three segments: Laurus Generics, Laurus Synthesis, and Laurus Bio. The Laurus Generics segment comprises API and FDF-Development, manufacture and sale of APIs and advanced intermediates and oral solid formulations/FDF. Laurus Synthesis segment comprises key starting materials (KSM), intermediates and APIs for new chemical entities (NCEs). Laurus Bio segment comprises recombinant products, animal origin free products for safer and viral free bio manufacturing. The Company operates through two geographical segments: Revenue from customers within India-Domestic, and Revenue from customers outside India-Exports. The Company sell its APIs in 56 countries.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
13
Last Close Price
392.4 INR
Average target price
369.3 INR
Spread / Average Target
-5.87%
Consensus
  1. Stock
  2. Equities
  3. Stock Laurus Labs Limited - NSE India S.E.